Home › Spinal Muscular Atrophy › Florida › Orlando
Spinal Muscular Atrophy clinical trials in Orlando, FL
3 studies for Spinal Muscular Atrophy are looking for participants at sites in and around Orlando (within about 30 miles). Open a study to see who can join and how to contact the study team.
Recruiting for a study here? Feature it at the top of this page — $99 for 30 days →
A Study to Assess the Safety, Tolerability, Efficacy, Pharmacokinetics, and Immunogenicity of Intravenous Administration of ARGX-119 in Pediatric Participants Aged 5 to Less Than 18 Years With Spinal Muscular Atrophy
RecruitingPhase 2
- Rare Disease Research FL LLC, Kissimmee · 16 mi away
A Study to Find Out How Nusinersen is Processed in the Body When Given Through the ThecaFlex DRx™ System in Adult and Pediatric Participants With Spinal Muscular Atrophy (PIERRE-PK)
RecruitingPhase 1
- Nemours Children's Hospital, Orlando, Orlando
Study of an Intrathecal Port and Catheter System for Subjects With Spinal Muscular Atrophy
Recruiting
- Nemours Children's Hospital, Florida, Orlando
About Spinal Muscular Atrophy
Spinal muscular atrophy (SMA) attacks nerve cells in the spinal cord, weakening voluntary muscles. Read about the genetics, types, and what may help.
More about Spinal Muscular Atrophy on MedlinePlus
Spinal Muscular Atrophy trials in other cities
- New York City, NY9 studies
- Mountain View, CA9 studies
- Philadelphia, PA7 studies
- Norfolk, VA6 studies
- Chicago, IL6 studies
- Grand Rapids, MI6 studies
- Boston, MA5 studies
- Houston, TX5 studies
- Lewisville, TX4 studies
- Little Rock, AR4 studies
- Aurora, CO4 studies
- Phoenix, AZ4 studies
Other studies in Orlando
- Non-Small Cell Lung Cancer44 studies
- Obesity31 studies
- Metastatic Cancer29 studies
- Overweight27 studies
- Alzheimer's Disease25 studies
- Type 2 Diabetes24 studies
- Cancer (all types)24 studies
- Breast Cancer23 studies
- Ovarian Cancer22 studies
- Ulcerative Colitis22 studies
- Lung Cancer21 studies
- Colorectal Cancer19 studies
From ClinicalTrials.gov, data retrieved Oct 5, 2026. Each study sets its own eligibility; the study team decides who can join.